Ic Verma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ic Verma has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Renu Saxena
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India
7 shared publications Sudha Kohli
Genetic Medicine, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India
5 shared publicationsSunita Bijarnia
Departments of Genetic Medicine, Sir Ganga Ram Hospital, New Delhi, India
3 shared publicationsR Saxena
Department of Genetic Medicine, Sir Ganga Ram Hospital, New Delhi
2 shared publicationsR. Saxena
2 shared publicationsAk Grover
Departments of Ophthalmology, Sir Ganga Ram Hospital, New Delhi, India
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S272-S273
1820 CTLA-4 +49 G/A polymorphism is associated with lymph node metastasis: A study in 500 North Indian breast cancer patients
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S272-S273
1820 CTLA-4 +49 G/A polymorphism is associated with lymph node metastasis: A study in 500 North Indian breast cancer patients
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S134
802 Next generation sequencing for diagnosis of patients with hereditary breast and ovarian cancer
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S134
802 Next generation sequencing for diagnosis of patients with hereditary breast and ovarian cancer
- Open Access
- 28 July 2011
- Published by Scientific Scholar in Cytojournal
- Vol. 8 (1) , 14
Utility of a limited panel of calretinin and Ber-EP4 immunocytochemistry on cytospin preparation of serous effusions: A cost-effective measure in resource-limited settings
Background: Differentiation between reactive, but morphologically atypical, mesothelial cells and adenocarcinoma in effusions can be problematic. Elaborate immunohistochemical panels have been devised. Techniques like DNA analysis, flow/image cytometry, and K-ras mutation analysis are research oriented and difficult to perform in routine, especially in resource-poor centers. We evaluated the efficacy of a limited two-antibody panel comprising calretinin and Ber-EP4 on cytospin and cell block preparations, in 100 effusion samples. Materials and Methods: Fifty cases of reactive mesothelial hyperplasia and 50 cases of adenocarcinoma diagnosed by cytomorphology in ascitic/pleural fluid specimens over a 2-year period were assessed. The diagnoses were confirmed by clinical/histopathologic correlation. Cytospin smears were made in all. Cell blocks were prepared, wherever adequate fluid was available. Immunocytochemistry (ICC) for calretinin and Ber-EP4 was performed. Results: Forty-five of the reactive effusion cases (90%) were calretinin reactive and Ber-EP4 negative. Among the adenocarcinoma cases, 49 (98%) were calretinin negative but Ber-EP4 positive. Thus, both calretinin and Ber-EP4 had a high sensitivity (90% and 98%, respectively), as well as a high specificity (100% and 86%, respectively). In the 21 reactive mesothelial cases, whose cell blocks were made, results were comparable to those on cytospin. However, of the 19 adenocarcinoma cases in which cell blocks were prepared, all were Ber-EP4 immunopositive except for three, which were positive on cytospin, implying false-negative results on cell blocks. Conclusions: A limited panel of two monoclonal antibodies, calretinin and Ber-EP4, may be useful in cytology, as a “primary antibody panel”, for accurate diagnosis and patient management. Additionally, ICC can be performed easily on cytospin preparations, which gave results comparable to cell blocks in our study.
- 28 July 2011
- Published by Scientific Scholar in Cytojournal
- Vol. 8 (1) , 14
Open AccessUtility of a limited panel of calretinin and Ber-EP4 immunocytochemistry on cytospin preparation of serous effusions: A cost-effective measure in resource-limited settings
Background: Differentiation between reactive, but morphologically atypical, mesothelial cells and adenocarcinoma in effusions can be problematic. Elaborate immunohistochemical panels have been devised. Techniques like DNA analysis, flow/image cytometry, and K-ras mutation analysis are research oriented and difficult to perform in routine, especially in resource-poor centers. We evaluated the efficacy of a limited two-antibody panel comprising calretinin and Ber-EP4 on cytospin and cell block preparations, in 100 effusion samples. Materials and Methods: Fifty cases of reactive mesothelial hyperplasia and 50 cases of adenocarcinoma diagnosed by cytomorphology in ascitic/pleural fluid specimens over a 2-year period were assessed. The diagnoses were confirmed by clinical/histopathologic correlation. Cytospin smears were made in all. Cell blocks were prepared, wherever adequate fluid was available. Immunocytochemistry (ICC) for calretinin and Ber-EP4 was performed. Results: Forty-five of the reactive effusion cases (90%) were calretinin reactive and Ber-EP4 negative. Among the adenocarcinoma cases, 49 (98%) were calretinin negative but Ber-EP4 positive. Thus, both calretinin and Ber-EP4 had a high sensitivity (90% and 98%, respectively), as well as a high specificity (100% and 86%, respectively). In the 21 reactive mesothelial cases, whose cell blocks were made, results were comparable to those on cytospin. However, of the 19 adenocarcinoma cases in which cell blocks were prepared, all were Ber-EP4 immunopositive except for three, which were positive on cytospin, implying false-negative results on cell blocks. Conclusions: A limited panel of two monoclonal antibodies, calretinin and Ber-EP4, may be useful in cytology, as a “primary antibody panel”, for accurate diagnosis and patient management. Additionally, ICC can be performed easily on cytospin preparations, which gave results comparable to cell blocks in our study.
- 1 April 2010
- Vol. 127 (4) , 480
Novel human pathological mutations. Gene symbol: TP53. Disease: Li-Fraumeni syndrome.
- 1 April 2010
- Vol. 127 (4) , 480
Novel human pathological mutations. Gene symbol: TP53. Disease: Li-Fraumeni syndrome.
- 1 April 2010
- Vol. 127 (4) , 480
Novel human pathological mutations. Gene symbol: Zmpste24. Disease: Restrictive dermopathy.
- 1 April 2010
- Vol. 127 (4) , 480
Novel human pathological mutations. Gene symbol: Zmpste24. Disease: Restrictive dermopathy.
- 1 April 2010
- Vol. 127 (4) , 485
Novel human pathological mutations. Gene symbol: PAX3. Disease: Waardenburg syndrome.
- 1 April 2010
- Vol. 127 (4) , 485
Novel human pathological mutations. Gene symbol: PAX3. Disease: Waardenburg syndrome.
- 1 April 2010
- Vol. 127 (4) , 485
Novel human pathological mutations. Gene symbol: UGT1A1. Disease: Crigler-Najjar syndrome 1.
- 1 April 2010
- Vol. 127 (4) , 485
Novel human pathological mutations. Gene symbol: UGT1A1. Disease: Crigler-Najjar syndrome 1.
- 1 April 2010
- Vol. 127 (4) , 488
Novel human pathological mutations. Gene symbol: TYR. Disease: Albinism, oculocutaneous 1.
- 1 April 2010
- Vol. 127 (4) , 488
Novel human pathological mutations. Gene symbol: TYR. Disease: Albinism, oculocutaneous 1.
- Open Access
- 1 January 2005
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 53 (3) , 167-71
Leber′s hereditary optic neuropathy with molecular characterization in two Indian families
PURPOSE: Leber's hereditary optic neuropathy (LHON) presents in early adulthood with painless progressive blindness of one or both eyes. Usually there is a positive family history of similar disease on the maternal side. Definitive diagnosis can be established by finding the change in the mitochondrial gene. No molecular studies have been reported from India. MATERIAL AND METHODS: Clinical, ophthalmologic and molecular studies were carried out in two patients from different families and available first degree relatives. The subjects were tested for the three common mutations seen in LHON by molecular techniques of polymerase chain reaction using mutation specific primers. RESULTS: The mutations G3460A and G11778A in the mitochondrial genes MTND1 and MTND4, known to be causative for LHON, were found in one family each. CONCLUSION: Diagnosis of LHON should be considered in familial cases and in young adults with optic atrophy. Confirmation of diagnosis should be sought by molecular gene analysis. Genetic counselling should be offered to all 'at risk' relatives of a patient harbouring the mutation.
- 1 January 2005
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 53 (3) , 167-71
Open AccessLeber′s hereditary optic neuropathy with molecular characterization in two Indian families
PURPOSE: Leber's hereditary optic neuropathy (LHON) presents in early adulthood with painless progressive blindness of one or both eyes. Usually there is a positive family history of similar disease on the maternal side. Definitive diagnosis can be established by finding the change in the mitochondrial gene. No molecular studies have been reported from India. MATERIAL AND METHODS: Clinical, ophthalmologic and molecular studies were carried out in two patients from different families and available first degree relatives. The subjects were tested for the three common mutations seen in LHON by molecular techniques of polymerase chain reaction using mutation specific primers. RESULTS: The mutations G3460A and G11778A in the mitochondrial genes MTND1 and MTND4, known to be causative for LHON, were found in one family each. CONCLUSION: Diagnosis of LHON should be considered in familial cases and in young adults with optic atrophy. Confirmation of diagnosis should be sought by molecular gene analysis. Genetic counselling should be offered to all 'at risk' relatives of a patient harbouring the mutation.
- 1 April 2003
- Vol. 70 (4)
Triple A syndrome--diagnostic and management issues.